Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
BackgroundAtezolizumab plus bevacizumab has been proved to have promising antitumor activity and tolerable safety in patients with unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) also demonstrated high response rates and favorable survival for patients with...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.929141/full |
| _version_ | 1811315744458145792 |
|---|---|
| author | Yujing Xin Fei Cao Hongcai Yang Xinyuan Zhang Yi Chen Xiaojing Cao Xiang Zhou Xiao Li Jinxue Zhou |
| author_facet | Yujing Xin Fei Cao Hongcai Yang Xinyuan Zhang Yi Chen Xiaojing Cao Xiang Zhou Xiao Li Jinxue Zhou |
| author_sort | Yujing Xin |
| collection | DOAJ |
| description | BackgroundAtezolizumab plus bevacizumab has been proved to have promising antitumor activity and tolerable safety in patients with unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) also demonstrated high response rates and favorable survival for patients with advanced HCC. This study aimed to explore the preliminary clinical efficacy and safety of atezolizumab plus bevacizumab combined with HAIC for patients with treatment-naive advanced HCC.MethodsBetween October 2020 and September 2021, patients with advanced HCC who initially received atezolizumab plus bevacizumab combined with HAIC of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) from three hospitals in China were reviewed for eligibility. The efficacy was evaluated by tumor response rate and survival, and the safety was evaluated by the frequency of key adverse events (AEs).ResultsIn total, 52 eligible patients with advanced HCC who received triple therapy were included in this study. The objective response rates (ORRs) based on mRECIST and RECIST1.1 criteria were 67.3% and 44.2%, respectively. The median progression-free survival (PFS) of patients was 10.6 months (95% CI, 8.37–13.8), and the overall survival (OS) was not reached. Extrahepatic metastasis was an independent risk factor associated with PFS. All AEs were controlled and no treatment-related deaths occurred.ConclusionAtezolizumab plus bevacizumab combined with HAIC-FOLFOX had a significant therapeutic effect and manageable AEs in patients with advanced HCC, which may be a potential treatment option for advanced HCC. |
| first_indexed | 2024-04-13T11:35:45Z |
| format | Article |
| id | doaj.art-e46df57fdac94c8d80e64ab59aa31b9d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T11:35:45Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e46df57fdac94c8d80e64ab59aa31b9d2022-12-22T02:48:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.929141929141Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinomaYujing Xin0Fei Cao1Hongcai Yang2Xinyuan Zhang3Yi Chen4Xiaojing Cao5Xiang Zhou6Xiao Li7Jinxue Zhou8Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, ChinaBackgroundAtezolizumab plus bevacizumab has been proved to have promising antitumor activity and tolerable safety in patients with unresectable hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) also demonstrated high response rates and favorable survival for patients with advanced HCC. This study aimed to explore the preliminary clinical efficacy and safety of atezolizumab plus bevacizumab combined with HAIC for patients with treatment-naive advanced HCC.MethodsBetween October 2020 and September 2021, patients with advanced HCC who initially received atezolizumab plus bevacizumab combined with HAIC of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) from three hospitals in China were reviewed for eligibility. The efficacy was evaluated by tumor response rate and survival, and the safety was evaluated by the frequency of key adverse events (AEs).ResultsIn total, 52 eligible patients with advanced HCC who received triple therapy were included in this study. The objective response rates (ORRs) based on mRECIST and RECIST1.1 criteria were 67.3% and 44.2%, respectively. The median progression-free survival (PFS) of patients was 10.6 months (95% CI, 8.37–13.8), and the overall survival (OS) was not reached. Extrahepatic metastasis was an independent risk factor associated with PFS. All AEs were controlled and no treatment-related deaths occurred.ConclusionAtezolizumab plus bevacizumab combined with HAIC-FOLFOX had a significant therapeutic effect and manageable AEs in patients with advanced HCC, which may be a potential treatment option for advanced HCC.https://www.frontiersin.org/articles/10.3389/fimmu.2022.929141/fullatezolizumabbevacizumabhepatic arterial infusion chemotherapyFOLFOXadvanced hepatocellular carcinoma |
| spellingShingle | Yujing Xin Fei Cao Hongcai Yang Xinyuan Zhang Yi Chen Xiaojing Cao Xiang Zhou Xiao Li Jinxue Zhou Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma Frontiers in Immunology atezolizumab bevacizumab hepatic arterial infusion chemotherapy FOLFOX advanced hepatocellular carcinoma |
| title | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
| title_full | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
| title_fullStr | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
| title_full_unstemmed | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
| title_short | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
| title_sort | efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma |
| topic | atezolizumab bevacizumab hepatic arterial infusion chemotherapy FOLFOX advanced hepatocellular carcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.929141/full |
| work_keys_str_mv | AT yujingxin efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT feicao efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT hongcaiyang efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT xinyuanzhang efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT yichen efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT xiaojingcao efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT xiangzhou efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT xiaoli efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma AT jinxuezhou efficacyandsafetyofatezolizumabplusbevacizumabcombinedwithhepaticarterialinfusionchemotherapyforadvancedhepatocellularcarcinoma |